Off-Target Screening of Biotherapeutics

Biotherapeutics cross-reactivity

Toxicity due to off-target binding to either cell surface or secreted proteins is a serious cause for concern in drug development. Furthermore,demonstrating on-target specificity is a necessary hurdle in the race for regulatory approval for a novel biotherapeutic.

Retrogenix’s Cell Microarray screening provides an understanding of the off-target binding potential of a biologic candidate during discovery and early development. Building a picture of a biotherapeutic’s ‘toxic liability’ helps reduce risk through more informed safety assessment and can save considerable time and resources by allowing bad drugs to fail earlier. Retrogenix’s off target screening data has been used extensively in regulatory submissions for clinical studies and marketing approval where high confidence in the specificity of a novel biotherapeutic is required.

Where Retrogenix results have been used in regulatory submissions:

  • Data were accepted globally, with IND/BLA submissions to: US FDA, EMA (Europe), PMDA (Japan) & NMPA (China)
  • Over a third of submissions that included Retrogenix results relied solely on these data for specificity assessment, with no tissue cross-reactivity (TCR) studies (38%)
  • 90% of submissions using Retrogenix data have been approved to date.

More details of the use of Retrogenix data can be found in our regulatory submissions survey results.

Retrogenix off target profiling:

  • The only platform for assessing for off-targets against both plasma membrane and secreted proteins that are expressed in human cells
  • Highly specific with very low numbers of false positives/negatives
  • Can predict/explain reduced bioavailability due to off-target binding
  • Can inform pre-clinical tox model selection, reducing animal testing
  • Helps prioritise drug leads or avoid off-target activities in next-generation of molecules

Low false positive rate

Our highly specific screen typically reports one or two confirmed interactions rather than 100s of erroneous results that can often be seen with protein microarrays. This saves months of validation work and avoids unnecessary investigations that could stall progress with regulatory submissions.

Please contact us to discuss an off-target project.

Screen for off-targets of:

  • Antibodies & bispecifics
  • ADCs
  • ScFvs, Fabs or antibody derivatives
  • Whole CAR T cells
  • Peptides
  • Protein ligands
  • Labelled small molecules

Retrogenix data in regulatory applications

To help with understanding the role of Retrogenix specificity assessment in regulatory submissions, and to quantify the extent to which it is replacing methods such as tissue cross reactivity (TCR) screening, we undertook a survey to find out how recently screened biotherapeutics are progressing. Pharma, biotech and non-profit sponsors who have undertaken at least one project in the past two years were surveyed – read more here….

See survey results

 

Correcting specificity in an antibody therapeutic

A recent publication describes how an anti-PD1 antibody, which caused the unique side-effect of capillary hemangioma in early phase clinical studies, was screened using Retrogenix technology and found to bind to off-target receptors that are biologically relevant to the formation of hemangioma. Subsequent molecular remodelling of the antibody not only eradicated the in vitro off-target binding but also led to increased potency in PD1/PD-L1 blockade…

Read the case study

Talk to us about a project
Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
glycotope_logo
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Capella Bioscience Logo
Sanofi Logo
Unum Theraputics Logo
Celyad Logo
…working with you was exactly like working with an experienced and knowledgeable scientific collaborator. We had the same types of discussions and strategic planning sessions and I felt confident throughout that we were addressing the issues in the best way possible. It was fun and if I see the opportunity we would do this again.
Professor Mark Kahn, University of Pennsylvania